HRP20050250A2 - Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor - Google Patents

Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor

Info

Publication number
HRP20050250A2
HRP20050250A2 HR20050250A HRP20050250A HRP20050250A2 HR P20050250 A2 HRP20050250 A2 HR P20050250A2 HR 20050250 A HR20050250 A HR 20050250A HR P20050250 A HRP20050250 A HR P20050250A HR P20050250 A2 HRP20050250 A2 HR P20050250A2
Authority
HR
Croatia
Prior art keywords
tfg
inhibitor
growth factor
transforming growth
oxazole compounds
Prior art date
Application number
HR20050250A
Other languages
English (en)
Inventor
Cook Blumberg Laura
John Munchhof Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20050250A2 publication Critical patent/HRP20050250A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20050250A 2002-09-18 2005-03-17 Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor HRP20050250A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02
PCT/IB2003/003823 WO2004026863A1 (en) 2002-09-18 2003-09-08 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
HRP20050250A2 true HRP20050250A2 (en) 2005-10-31

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050250A HRP20050250A2 (en) 2002-09-18 2005-03-17 Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor

Country Status (28)

Country Link
US (1) US7273936B2 (es)
EP (1) EP1542994B1 (es)
JP (1) JP4518956B2 (es)
KR (1) KR20050057415A (es)
CN (1) CN1681810A (es)
AP (1) AP2005003261A0 (es)
AR (1) AR041273A1 (es)
AT (1) ATE430147T1 (es)
AU (1) AU2003256003A1 (es)
BR (1) BR0314383A (es)
CA (1) CA2499429C (es)
CO (1) CO5550473A2 (es)
CR (1) CR7743A (es)
DE (1) DE60327443D1 (es)
EA (1) EA200500354A1 (es)
ES (1) ES2323421T3 (es)
HR (1) HRP20050250A2 (es)
IS (1) IS7711A (es)
MA (1) MA27443A1 (es)
MX (1) MXPA05002332A (es)
NO (1) NO20051838L (es)
OA (1) OA12926A (es)
PA (1) PA8582701A1 (es)
PE (1) PE20040987A1 (es)
PL (1) PL375975A1 (es)
TW (1) TW200413362A (es)
UY (1) UY27978A1 (es)
WO (1) WO2004026863A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
PL375979A1 (en) * 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
KR20070049655A (ko) * 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
WO2006028029A1 (ja) * 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2629432A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
EP2154965A4 (en) * 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
US8268874B2 (en) 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
EP3638235A4 (en) * 2017-06-14 2021-06-09 Trevena, Inc. COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING IT
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2021101854A1 (en) 2019-11-19 2021-05-27 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
EP1357116A4 (en) 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ES2237671T3 (es) 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
CA2450400A1 (en) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors

Also Published As

Publication number Publication date
CN1681810A (zh) 2005-10-12
US20040110797A1 (en) 2004-06-10
CO5550473A2 (es) 2005-08-31
ES2323421T3 (es) 2009-07-15
EA200500354A1 (ru) 2005-10-27
AR041273A1 (es) 2005-05-11
WO2004026863A1 (en) 2004-04-01
BR0314383A (pt) 2005-07-19
AU2003256003A1 (en) 2004-04-08
PE20040987A1 (es) 2004-12-27
JP4518956B2 (ja) 2010-08-04
MA27443A1 (fr) 2005-07-01
US7273936B2 (en) 2007-09-25
CA2499429A1 (en) 2004-04-01
DE60327443D1 (de) 2009-06-10
WO2004026863A8 (en) 2005-04-21
EP1542994B1 (en) 2009-04-29
EP1542994A1 (en) 2005-06-22
ATE430147T1 (de) 2009-05-15
UY27978A1 (es) 2004-04-30
TW200413362A (en) 2004-08-01
PL375975A1 (en) 2005-12-12
CR7743A (es) 2005-06-15
JP2006502235A (ja) 2006-01-19
AP2005003261A0 (en) 2005-03-31
KR20050057415A (ko) 2005-06-16
CA2499429C (en) 2010-09-21
NO20051838L (no) 2005-04-15
OA12926A (en) 2006-10-13
IS7711A (is) 2005-02-24
MXPA05002332A (es) 2005-06-08
PA8582701A1 (es) 2004-04-23

Similar Documents

Publication Publication Date Title
HRP20050250A2 (en) Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor
AP2005003264A0 (en) Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
PL375974A1 (en) Triazole derivatives as transforming growth factor (tgf) inhibitors
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2003239272A1 (en) Fluorescent compositions comprising diketopyrrolopyrroles
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003286711A1 (en) Indazolinone compositions useful as kinase inhibitors
AU2002351179A1 (en) Glycinamides as factor xa inhibitors
AU2003202263A1 (en) Roh-kinase inhibitors
AU2003211931A1 (en) Jnk inhibitor
AU2003225031A1 (en) Eptfe-reinforced perfluoroelastomers
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
HK1071886A1 (en) Novel compounds and compositions as cathepsin inhibitors
AU2003256805A1 (en) Compounds compositions and methods
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003211385A1 (en) Azole compounds
AU2003255333A1 (en) Pyrazole inhibitors of the transforming growth factor
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
AU2003289287A1 (en) Jnk inhibitor
AU2003239508A1 (en) Indole compounds useful as impdh inhibitors
AU2003220930A1 (en) Emthod of screening transporter inhibitor
AU2003228450A1 (en) Inhibition of tumor growth via peroxiredoxin 3
AU2002325882A1 (en) Phenyl derivatives as factor Xa inhibitors

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050321

Year of fee payment: 3

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
OBST Application withdrawn